___

• Kelleher JP, Centorrino F, Albert MJ, Baldessarini RJ. Advances in atypical antipsychotics for the treatment of schizophrenia: New formulations and new agents. CNS Drugs 2002; 16:249-261.
• Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005; 66:504-514.
• Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: A systematic review. Schizophr Res 2004;71(2-3):195-212.
• Çelik GG, Tahiroğlu AY, Avcı A. Çocuk ve ergenlerde atipik antipsikotik ilaçların metabolik ve endokrin yan etkileri. Psikiyatride Güncel Yaklaşımlar 2011; 3:232-250.
• Dixon L, Perkins D, Calmes C. Guideline Watch (September 2009): Practice guideline for treatment of patients with schizophrenia. Washinton D.C., American Psychiatric Association, 2009.
• Savaş HA, Yumru M, Savaş E. Psikofarmakoterapinin yol açtığı kilo alımına karşı ilâçla tedavi yaklaşımları. Yeni Symposium 2007; 45:35-40.
• Mario AJ, Cesar GB, Jose VB, Rocio PI, Obdulia MG,Teresa PP et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients:a randomized controlled trial. J Clin Psychiatry 2006; 67:1253-1260.
• Hagg S, Joelsson L, Mjorndal T. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59:294-299.
• Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: A double-blind, placebo-controlled study. Am J Psychiatry 2008; 165:352- 358.
• Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007; 1:CD005148.
• Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156:1686-1696.
• Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: Another high-risk group for type 2 diabetes. Diabetes Care 2003; 26:1597-1605.
• Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009; 119:171-179.
• Stahl SM. Neuropharmacology of obesity:my receptors make me eat. J Clin Psychiatry 1998; 59:447-448.
• Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005; 54:862-871.
• Kraus T, Haack M, Schuld A, Hinze-Selch D, Kühn M, Uhr M et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156:312-314.
• Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61:742-749.
• Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002; 26:137-141.
• Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment: Pharmacological mechanisms. Pharmacol Ther 2010; 125:169-179.
• Şengül C, Herken H. Antipsikotiklere bağlı kilo alımının farmakogenetiği. Klinik Psikofarmakoloji Bülteni 2009; 19:297-303.
• Yazıcı K, Yazıcı A. Antipsikotik ilaçların yol açtığı kilo artışı: Genlerin payı ne? Klinik Psikofarmakoloji Bülteni 2008; 18:59-70.
• Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: A frequently sampled intravenous glucose tolerance test and minimal modal analysis. Arch Gen Psychiatry 2005; 62:19-28.
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223.
• Baptista T, Kin NM, Beaulie S, Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug adminitration: Mechanism, management and research perspectives. Pharmacopsychiatry 2002; 35:205-219.
• Weterling T. Bodyweight gain with atypical antipsychotics:comparative review. Drug Saf 2001; 24:59-73.
• Kinon BJ, Basson MS, Gilmore LM. Long term olanzapine treatment, weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 1993; 54:272- 276.
• Miller LJ, Pharm D. Management of atypical antipsychotic drug-induced weight gain: Focus on metformin. Pharmacotherapy 2009; 29:725-735.
• Hummer M, Kemler G, Kurz M, Kurzthaler I, Oberbauer H, Fleischhacker WW. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995; 5:437-440.
• Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF et al. Lifestyle intervention and metformin for treatment of antipsychotic induced weight gain: A randomized controlled trial. JAMA 2008; 299:185-193.
• Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005; 353:2111-2120.
• Özenoğlu A, Uğurlu S, Can G, Eker E, Elmacıoğlu F. Psikiyatrik tedavilerle gelişen metabolik bozukluklar ve tedavisinde diyetetik yaklaşımın önemi. Nobel Medicus 2009; 5(Ek 1):36-44
• Bergman LB, Asplund AB, Lindh JD. Metformin for weight in non-diabetic patients on antipsychotic drugs: A systematic review and meta-analysis. J Psychopharmacology 2010;doi:10.1177/0269881109353461.
• Seufert J, Lubben G, Dietrich K, Bates PC. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. Clin Ther 2004; 26:805-818.
• Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002; 159:655-657.
• Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescent. Am J Psychiatry 2006; 163:2072-2079.
• Arman S, Sadramely MR, Nadi M, Koleini N. A randomized, placebo controlled, double-blind trial of metformin for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J 2008; 29:1130-1134.
• Baptista T, Martínez J, Lacruz A, Rangel N, Beaulieu S, Serrano A et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: A double-blind placebo-controlled trial. Can J Psychiatry 2006; 51:192-196.
• Baptista T, Rangel N, Frenández V, Carrizo E, Fakih YE, Uzcátegui E et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo- controlled trial. Schizophr Res 2007; 93:99-108.
• Baptista T, Uzcátegui M, Rangel N, Fakih YE, Galeazzi T, Beaulieu S et al. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: A 12-week double-blind, placebo-controlled pilot study. Psychiatry Res 2008; 159:250-253.
• Chen CH, Chiu CC, Huang MC, Wu TH, Liu HC, Lu ML. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:925-931.
• Carrizo E, Frenández V, Connell L, Sandia I, Prieto D, Mogollón J et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: A 14 week, double-blind, paralel group, placebo-controlled study. Schizophr Res 2009; 113:19-26.